Tuesday, June 6, 2023
Home Authors Posts by Editor / Curator

Editor / Curator

755 POSTS 0 COMMENTS
Accelerator

Report: Expedia, Doordash, eCommerce Fashion Retailer and YouTube All Rolled Into...

Editor / Curator -
All News

Is Smart for Life (SMFL) $4.30, a Bargain Post Reverse Split?

Editor / Curator -
Psychedelic Stock Review

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

Editor / Curator -
Psychedelic Stock Review

The Ketamine Endgame. Silo Pharmaceutical (SILO).

Editor / Curator -
Psychedelic Stock Review

The Ketamine Cure (NY Times)

Editor / Curator -
All News

A Good Bear Market, is a Terrible Thing to Waste. How...

Editor / Curator -
2023 Watch List

The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel...

Editor / Curator -
2022 Watch List

Ardelyx (ARDX) Resubmits New Drug Application to FDA.

Editor / Curator -
Psychedelic Stock Review

Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.

Editor / Curator -
ARDX, Roland Rick Perry
2022 Watch List

And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.

Editor / Curator -
123...76Page 2 of 76

Latest article

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

2022 Watch List Editor / Curator -
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

2020 Watch List Editor / Curator -
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

2023 Watch List Editor / Curator -
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.